ERYTECH positions its lead product in solid tumors and launches a Phase II clinical study in pancreatic cancer

ERYTECH provides an update on its development plans to broaden the scope of its lead product eryaspase into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.

Menu